Logo

Genome Therapeutics, Genesoft Move Forward with Merger Plans

Dec 30, 2003

NEW YORK, Dec. 30 (GenomeWeb News) - Genome Therapeutics and Genesoft Pharmaceuticals today announced that the US Securities and Exchange Commission has approved a registration statement related to their proposed merger that includes a proxy statement that will be mailed to shareholders of both companies.

In addition, the companies said they will each hold a special meeting of their stockholders to vote on the proposed merger and other related matters on Feb. 2, 2004.

The all-stock transaction, originally announced in November, is expected to close in the first quarter of 2004, subject to various closing conditions, including the approval by both companies' shareholders.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.